MiMedx Group, Inc s trend and data analysis indicates that the stock price has dropped -0.11% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 3.15% . Looking at the past 52 week period, the stock price is up at 6.5% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of MiMedx Group, Inc has a positive value of 7.3 compared to overall market.MiMedx Group, Inc. is having a Relative Strength Index of 63.3 which indicates the stock is not yet over sold or over bought based on the technical indicators.
MiMedx Group, Inc (NASDAQ:MDXG) has climbed 1.84% in the past week and advanced 6.76% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 1.6% and the outperformance has advanced to 5.54% for the last 4 weeks period.
For the current week, the company shares have a recommendation consensus of Buy. MiMedx Group, Inc (NASDAQ:MDXG) : On Friday heightened volatility was witnessed in MiMedx Group, Inc (NASDAQ:MDXG) which led to swings in the share price. The stock opened for trading at $8.58 and hit $8.98 on the upside , eventually ending the session at $8.85, with a gain of 2.19% or 0.19 points. The heightened volatility saw the trading volume jump to 1,697,610 shares. The 52-week high of the share price is $10.02 and the company has a market cap of $963 million. The 52-week low of the share price is at $6.64 .
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.MiMedx Group Inc was Initiated by Piper Jaffray on Mar 3, 2017 to Overweight, Price Target of the shares are set at $10.MiMedx Group Inc was Initiated by Piper Jaffray on Mar 3, 2017 to Overweight, Price Target of the shares are set at $10.
Company has reported several Insider transactions to the SEC, on Mar 15, 2017, Charles E Koob (director) sold 50,486 shares at 8.50 per share price.On Mar 8, 2017, William Charles Taylor (President and COO) sold 26,000 shares at 8.18 per share price.On May 23, 2016, Parker H Petit (CEO) purchased 20,000 shares at 6.99 per share price.
MiMedx Group Inc Last issued its quarterly earnings results on Feb 23, 2017. The company reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $0.07. The company had revenue of $69.90 million for the quarter, compared to analysts expectations of $70.71 million. The companys revenue was up 34.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.07 EPS.
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.